Targeting cancer expressed EGFR with a humanized monoclonal antibody
The humanization of mouse monoclonal antibodies targeting tumor antigens allows for the safe and repeated administration of therapeutic antibodies to humans. Previously, we reported on mouse monoclonal antibody 40H3 and its reactivity with a conformational epitope exposed on EGFR when...
Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models
Abstract Health technology assessments (HTAs) for targeted therapies like osimertinib require models capturing individual pharmacokinetic/pharmacodynamic (PK/PD) variability in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Traditional models often fail to reflect these dynamics adequately. This study compared...
Dr Girard on Updated Data From the PALOMA-2 Trial in EGFR-Mutant NSCLC
Dr Girard on Updated Data From the PALOMA-2 Trial in EGFR-Mutant NSCLC Nicolas Girard, MD, PhD, discusses updated data from the phase 2 PALOMA-2 trial (NCT05498428) that were presented at the 2026 European Lung Cancer Congress. “The results are [relatively]...
Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLC
Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLC Sac-TMT offered significant survival benefits vs docetaxel in pretreated EGFR-mutated NSCLC. The TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) displayed a significant overall survival (OS) benefit compared with docetaxel in patients with pretreated EGFR-mutated...
Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy
Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy Published on 03/27/2026 at 12:28 pm EDT Publicnow Share SUMMIT THERAPEUTICS INC. -4.17% Health-Related Quality of Life...
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutant NSCLC: Final OS from OptiTROP-Lung03
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutant NSCLC: Final OS from OptiTROP-Lung03 Patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) face limited treatment options after progression on EGFR tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy. Outcomes in this setting remain...
Natural compounds for non-small cell lung cancer treatment: focus on the EGFR signaling pathway
The EGFR signaling pathway is a critical driver in the occurrence and development of non-small cell lung cancer (NSCLC). However, the inevitable development 1 Introduction Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer...
CIRCLE-F/V: a dual-mode CRISPR-Cas13a cascade biosensor for ultrasensitive and visual detection of low-abundance EGFR mutations
Abstract Precise identification of low-frequency EGFR L858R mutations is crucial for targeted therapy and prognosis in non-small cell lung cancer (NSCLC). Here, we present CIRCLE-F/V (CRISPR-based Integrated Restriction-assisted Cyclic Loop-mediated Enhancement Fluorescence/Visual platform), a dual-mode CRISPR-Cas13a cascade biosensor enabling ultrasensitive...
Discrepancy between cystatin C-based and creatinine-based eGFR predicts all-cause mortality in a community-based population: the Takahata study
AbstractBackground Discrepancies between the cystatin C-based estimated glomerular filtration rate (eGFRcys) and the creatinine-based estimated glomerular filtration rate (eGFRcr) have been linked to adverse outcomes in Western populations. However, their prognostic significance in community-dwelling Japanese individuals remains unclear. Therefore, we...